Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW2871 and High Dose Interferon-α2b in Metastatic Melanoma
NCT00679289Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Mar 2008
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ecromeximab in melanoma (3 cohorts), sponsored by Ludwig Cancer Research. Primary endpoints: Progression-Free Survival up to 17 months and Treatment-emergent Adverse Events up to 17 months. Started Mar 2008; status: completed.
02
Drugs
ecromeximab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00679289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00679289.